Clindamycin Therapy for Streptococcal Infections

Primary Treatment Considerations

The American Academy of Pediatrics and the Infectious Diseases Society of America recommend penicillin as the first-line agent for all streptococcal infections, with 100% susceptibility documented and no resistance reported worldwide 1
Clindamycin is recommended as a second-line alternative for patients with documented penicillin allergy at high risk for anaphylaxis, according to the Infectious Diseases Society of America 1

The Centers for Disease Control and Prevention suggest using clindamycin for patients with a documented history of anaphylaxis, angioedema, respiratory distress, or urticaria following penicillin or cephalosporin administration 1
The Infectious Diseases Society of America recommends susceptibility testing must be confirmed before initiating clindamycin therapy, as empirical use is not recommended due to varying resistance rates 1
The American College of Clinical Pharmacy states that the D-zone test is essential to detect inducible macrolide resistance that confers clindamycin resistance 1

The Infectious Diseases Society of America recommends using clindamycin combined with penicillin for necrotizing fasciitis or streptococcal toxic shock syndrome caused by Group A streptococci 2, 3, 4
Clindamycin suppresses streptococcal toxin and cytokine production, providing superior efficacy compared to penicillin alone in animal models and observational studies, according to the Clinical Infectious Diseases journal 2
The American College of Emergency Physicians notes that penicillin must be added to clindamycin due to potential clindamycin resistance (though <5% in the United States for Group A streptococci) 2

The American Academy of Pediatrics recommends clindamycin 20-30 mg/kg/day in three doses (maximum 300 mg per dose) for 10 days for penicillin treatment failures or suspected resistant streptococcal pharyngitis 4
The Infectious Diseases Society of America states that clindamycin and amoxicillin-clavulanate achieve high pharyngeal eradication rates in chronic streptococcal carriers 5, 6

The American College of Clinical Pharmacy recommends clindamycin 300-450 mg three times daily for skin and soft tissue infections 7
The Clinical Infectious Diseases journal suggests clindamycin 600-900 mg IV every 8 hours for necrotizing infections 2, 7
The Pediatric Infectious Diseases Society recommends clindamycin 10-13 mg/kg/dose IV every 6-8 hours (not to exceed 40 mg/kg/day) for complicated skin/soft tissue infections 7

The Centers for Disease Control and Prevention note that geographic variation in clindamycin resistance is substantial and must guide empirical therapy decisions, with macrolide resistance in the United States remaining <5% for Group A streptococci, but reaching 8.2% in Germany and 18.3% in Spain 2

The Infectious Diseases Society of America recommends never using clindamycin as monotherapy for Group A streptococcal necrotizing fasciitis or toxic shock syndrome—always combine with penicillin 2, 3
The American College of Clinical Pharmacy suggests avoiding empirical clindamycin without susceptibility testing, particularly in areas with high macrolide resistance rates 1
The Clinical Infectious Diseases journal recommends using vancomycin instead when susceptibility testing is unavailable or resistance is confirmed (1 g IV every 12 hours for adults) 1

The Infectious Diseases Society of America recommends clindamycin 300-450 mg orally three times daily for adults with skin/soft tissue infections 8
Clindamycin provides coverage for both CA-MRSA and beta-hemolytic streptococci, making it a suitable option for treating purulent cellulitis where both organisms are suspected 8, 9

The FDA warns that clindamycin carries a risk of Clostridioides difficile-associated disease, which may occur more frequently compared with other oral agents 8
Clindamycin achieved 97% streptococcal eradication by day 7 and 99% by day 14 in a pediatric study of streptococcal pyoderma, comparable to erythromycin and superior to penicillin 8